SCM Lifescience Past Earnings Performance
Past criteria checks 0/6
SCM Lifescience has been growing earnings at an average annual rate of 16%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 18.7% per year.
Key information
16.0%
Earnings growth rate
49.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 18.7% |
| Return on equity | -124.3% |
| Net Margin | -2,612.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How SCM Lifescience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 826 | -21,574 | 4,519 | 8,781 |
| 31 Dec 23 | 696 | -23,961 | 3,875 | 9,315 |
| 30 Sep 23 | 558 | -23,852 | 3,754 | 8,739 |
| 30 Jun 23 | 352 | -23,422 | 3,412 | 9,043 |
| 31 Mar 23 | 380 | -22,828 | 3,204 | 8,815 |
| 31 Dec 22 | 396 | -22,930 | 3,209 | 9,311 |
| 30 Sep 22 | 426 | -22,831 | 1,506 | 9,889 |
| 30 Jun 22 | 466 | -22,859 | 994 | 10,177 |
| 31 Mar 22 | 452 | -20,917 | -147 | 10,263 |
| 31 Dec 21 | 439 | -22,519 | 1,493 | 10,473 |
| 30 Sep 21 | 424 | -12,809 | 5,682 | 11,069 |
| 30 Jun 21 | 393 | -6,614 | 6,784 | 10,227 |
| 31 Mar 21 | 409 | -14,299 | 8,394 | 10,342 |
| 31 Dec 20 | 320 | -9,633 | 7,089 | 8,846 |
| 30 Sep 20 | 313 | -23,061 | 4,904 | 7,759 |
| 30 Jun 20 | 244 | -27,380 | 4,557 | 7,734 |
| 31 Mar 20 | 144 | -40,926 | 4,576 | 6,968 |
| 31 Dec 19 | 168 | -42,554 | 4,709 | 7,321 |
| 30 Sep 19 | 74 | -64,990 | 4,791 | 7,149 |
| 31 Dec 18 | 29 | -40,095 | 3,227 | 5,272 |
| 31 Dec 17 | 30 | -1,744 | 1,496 | 3,794 |
| 31 Dec 16 | 12 | -3,955 | 1,039 | 2,919 |
| 31 Dec 15 | 14 | -3,247 | 954 | 1,032 |
Quality Earnings: A298060 is currently unprofitable.
Growing Profit Margin: A298060 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A298060 is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare A298060's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A298060 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A298060 has a negative Return on Equity (-124.32%), as it is currently unprofitable.